- Home
- GPCR vs IMTX Comparison
GPCR vs IMTX Comparison
Compare GPCR & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPCR
- IMTX
- Stock Information
- Founded
- GPCR 2016
- IMTX N/A
- Country
- GPCR United States
- IMTX Germany
- Employees
- GPCR N/A
- IMTX N/A
- Industry
- GPCR
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GPCR
- IMTX Health Care
- Exchange
- GPCR Nasdaq
- IMTX Nasdaq
- Market Cap
- GPCR 1.2B
- IMTX 1.1B
- IPO Year
- GPCR 2023
- IMTX N/A
- Fundamental
- Price
- GPCR $33.00
- IMTX $9.04
- Analyst Decision
- GPCR Strong Buy
- IMTX Strong Buy
- Analyst Count
- GPCR 8
- IMTX 4
- Target Price
- GPCR $69.57
- IMTX $13.67
- AVG Volume (30 Days)
- GPCR 838.8K
- IMTX 679.4K
- Earning Date
- GPCR 11-06-2025
- IMTX 11-14-2025
- Dividend Yield
- GPCR N/A
- IMTX N/A
- EPS Growth
- GPCR N/A
- IMTX N/A
- EPS
- GPCR N/A
- IMTX N/A
- Revenue
- GPCR N/A
- IMTX $152,823,253.00
- Revenue This Year
- GPCR N/A
- IMTX N/A
- Revenue Next Year
- GPCR N/A
- IMTX $13.52
- P/E Ratio
- GPCR N/A
- IMTX N/A
- Revenue Growth
- GPCR N/A
- IMTX 83.61
- 52 Week Low
- GPCR $13.22
- IMTX $3.30
- 52 Week High
- GPCR $40.06
- IMTX $11.25
- Technical
- Relative Strength Index (RSI)
- GPCR 64.72
- IMTX 44.41
- Support Level
- GPCR $31.50
- IMTX $9.99
- Resistance Level
- GPCR $34.50
- IMTX $10.70
- Average True Range (ATR)
- GPCR 1.72
- IMTX 0.50
- MACD
- GPCR 0.29
- IMTX -0.29
- Stochastic Oscillator
- GPCR 85.30
- IMTX 13.89
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.